Research and Markets: Competitor Analysis: c-MET/HGF Inhibitors 2011

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/29db13/competitor_analysi) has announced the addition of La Merie's "Competitor Analysis: c-MET/HGF Inhibitors 2011" report to their comprehensive offering of the latest medical research publications.

This detailed intelligence report provides a competitor analysis in the development pipeline of novel emerging inhibitors of c-MET receptor tyrosine kinase (RTK) and its ligand hepatocyte growth factor (HGF) or scatter factor (SF) for treatment of solid tumors. Purchase of the downloadable pdf report includes 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail, allowing editing of the project data to print or export an individual report.

The c-MET signalling pathway consists of the mesenchymal epithelial transition factor (c-MET) transmembrane tyrosine kinase receptor and its ligand hepatocyte growth factor (HGF) or scatter factor (SF). Binding of HGF/SF to c-MET activates downstream signalling pathways such as Rho, focal adhesion kinase (FAK) and PI3K. These pathways regulate cancer cell growth, survival angiogenesis, invasion and metastasis. Thus, prevention of c-MET dependent neoplastic processes may provide a means for managing invasive tumors of high metastatic potential. c-MET/HGF has thus evolved as an attractive target for the pharmaceutical industry.

The report includes a compilation of currently active projects in research and development of c-Met/HGF inhibitors. In addition, the report lists company-specific R&D pipelines of c-Met/HGF inhibitors in R&D. Competitor projects are listed in a tabular format providing information on: drug codes, target/mechanism of action, class of compound, company, product category, indication, R&D Stage, and additional comments with a hyperlink leading to the source of information.

Companies Mentioned:

  • Abbott
  • Abxign 21 Amgen
  • ArQule 23 Astex Therapeutics
  • AVEO Pharmaceutical 26 Bristol-Myers Squibb (BMS)
  • Chroma Therapeutics 28 Daiichi Sankyo
  • Deciphera Pharmaceuticals 29 Eisai
  • Eli Lilly
  • Exelixis
  • Genmab
  • GlaxoSmithKline (GSK)
  • Hutchison MediPharma Limited
  • Johnson & Johnson
  • Kringle Pharmaceuticals
  • Kyowa Hakko Kirin
  • Merck & Co
  • Merck Serono
  • Methylgene
  • Novartis
  • Pfizer
  • Pieris
  • ProMetic BioTherapeutics Inc
  • Roche
  • Sanofi
  • Sigma-Tau
  • Simcere
  • Taiho pharmaceutical co
  • Takeda Pharmaceutical Co.
  • Tiger Pharmatech
  • Xcovery

For more information visit http://www.researchandmarkets.com/research/29db13/competitor_analysi

Contacts

Research and Markets
Laura Wood, Senior Manager,
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Sharing

Contacts

Research and Markets
Laura Wood, Senior Manager,
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716